Senti Biosciences (SNTI) Stock Price, News & Analysis

Company Overview

Senti Biosciences, Inc. (NASDAQ: SNTI) is a clinical‐stage biotechnology company focused on developing programmable cell and gene therapies through its proprietary synthetic biology platform. The company engineers living cells with precise genetic circuits designed to detect and respond to disease signals in real time. Senti’s modular Gene Circuits Platform integrates sensors, controllers and effectors to create therapies that sense disease environments and orchestrate controlled therapeutic responses.

Leveraging its technology, Senti is advancing a pipeline of engineered cell therapy candidates targeting oncology and other serious diseases. The company’s programs include allogeneic and autologous cell therapies equipped with safety switches and logic gating to enhance specificity and reduce off‐target effects. In addition to cell therapy, Senti is exploring in vivo gene circuit applications for chronic diseases, applying its design principles to deliver genes that activate only under predefined physiological conditions.

Founded in 2017 and headquartered in South San Francisco, Senti Biosciences grew out of pioneering work in synthetic biology at leading academic institutions. Since its inception, the company has entered strategic collaborations with major pharmaceutical partners to expand its research capabilities and accelerate clinical development. Senti operates research and manufacturing facilities in the San Francisco Bay Area, with plans to broaden its footprint as it progresses toward regulatory filings.

Senti Biosciences is led by President and Chief Executive Officer David Cannistra, who brings extensive experience in biotechnology growth and commercialization. Co‐founder Tim Lu, Ph.D., serves as Executive Chairman and drives the scientific vision, drawing on his background in synthetic biology and gene editing. The leadership team is complemented by seasoned experts in clinical development, regulatory affairs and manufacturing, positioning Senti to advance its next-generation therapies toward the clinic.

Key Stats

• Today's Range: $2.10 to $2.34
• 50-Day Range: $1.99 to $3.84
• 52-Week Range: $1.52 to $16.94
• Volume: 94,812 shs
• Average Volume: 651,236 shs
• Market Capitalization: $57.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Buy

Senti Biosciences Stock Analysis - MarketRank™

Senti Biosciences scored higher than 54% of companies evaluated by MarketBeat, and ranked 470th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Senti Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Senti Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Senti Biosciences are expected to grow in the coming year, from ($14.54) to ($1.88) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Senti Biosciences is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Senti Biosciences is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Senti Biosciences has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.56% of the float of Senti Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Senti Biosciences has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Senti Biosciences has recently increased by 79.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Senti Biosciences does not currently pay a dividend.

Dividend Growth

Senti Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.56% of the float of Senti Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Senti Biosciences has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Senti Biosciences has recently increased by 79.24%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.40

News Sentiment

Senti Biosciences has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Senti Biosciences this week, compared to 1 article on an average week.

Search Interest

2 people have searched for SNTI on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Senti Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.12% of the stock of Senti Biosciences is held by insiders.

Percentage Held by Institutions

Only 25.73% of the stock of Senti Biosciences is held by institutions.

SNTI Stock Analysis - Frequently Asked Questions

How have SNTI shares performed this year?

Senti Biosciences' stock was trading at $3.51 at the beginning of the year. Since then, SNTI stock has decreased by 37.0% and is now trading at $2.21.

How were Senti Biosciences' earnings last quarter?

Senti Biosciences, Inc. (NASDAQ:SNTI) issued its earnings results on Tuesday, May, 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by $0.85. The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $1.30 million.

When did Senti Biosciences' stock split?

Senti Biosciences's stock reverse split on Thursday, July 18th 2024.The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Senti Biosciences?

Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Senti Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Senti Biosciences investors own include NVIDIA (NVDA), PayPal (PYPL), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Coinbase Global (COIN) and SoFi Technologies (SOFI).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNTI
• CIK: 1854270
• Web: www.sentibio.com
• Phone: 650-239-2030
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.50
• High Stock Price Target: $12.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +284.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($10.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$52.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -177.24%
• Return on Assets: -67.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.22
• Quick Ratio: 4.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.31 per share
• Price / Book: 0.42

Miscellaneous

• Outstanding Shares: 26,081,000
• Free Float: 25,267,000
• Market Cap: $57.64 million
• Optionable: Not Optionable
• Beta: 2.09